Is IMA or MGNX more profitable?

ImageneBio has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. ImageneBio's return on equity of -38.96% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.96% -34.60% MacroGenics -44.79% -147.80% -28.40%

Does the media favor IMA or MGNX?

In the previous week, MacroGenics had 1 more articles in the media than ImageneBio. MarketBeat recorded 2 mentions for MacroGenics and 1 mentions for ImageneBio. MacroGenics' average media sentiment score of 1.00 beat ImageneBio's score of 0.00 indicating that MacroGenics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MacroGenics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ACIU or IMA more profitable?

ImageneBio has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. ImageneBio's return on equity of -38.96% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -1,788.02% -125.26% -40.85% ImageneBio N/A -38.96% -34.60%

Does the media favor ACIU or IMA?

In the previous week, AC Immune had 1 more articles in the media than ImageneBio. MarketBeat recorded 2 mentions for AC Immune and 1 mentions for ImageneBio. AC Immune's average media sentiment score of 0.86 beat ImageneBio's score of 0.00 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AVXL or IMA more profitable?

Anavex Life Sciences' return on equity of -32.73% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -32.73% -30.15% ImageneBio N/A -38.96% -34.60%

Does the media favor AVXL or IMA?

In the previous week, Anavex Life Sciences had 6 more articles in the media than ImageneBio. MarketBeat recorded 7 mentions for Anavex Life Sciences and 1 mentions for ImageneBio. Anavex Life Sciences' average media sentiment score of 0.62 beat ImageneBio's score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GALT or IMA more profitable?

Galectin Therapeutics' return on equity of 0.00% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -164.69% ImageneBio N/A -38.96% -34.60%

Does the media favor GALT or IMA?

In the previous week, Galectin Therapeutics and Galectin Therapeutics both had 1 articles in the media. Galectin Therapeutics' average media sentiment score of 0.67 beat ImageneBio's score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ImageneBio (IMA) Competitors

$5.64 +0.10 (+1.81%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$5.57 -0.07 (-1.24%)

As of 08/3/2026 04:10 PM Eastern

Compare

IMA vs. MGNX, SLGL, ACIU, AVXL, and GALT

Should you buy ImageneBio stock or one of its competitors? MarketBeat compares ImageneBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ImageneBio include MacroGenics (MGNX), Sol-Gel Technologies (SLGL), AC Immune (ACIU), Anavex Life Sciences (AVXL), and Galectin Therapeutics (GALT).

How does ImageneBio compare to MacroGenics?

ImageneBio (NASDAQ:IMA) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 2.2% of ImageneBio shares are held by company insiders. Comparatively, 13.6% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ImageneBio currently has a consensus target price of $30.00, indicating a potential upside of 431.91%. MacroGenics has a consensus target price of $5.50, indicating a potential upside of 43.98%. Given ImageneBio's higher probable upside, research analysts plainly believe ImageneBio is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

ImageneBio has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	75.08	-$45.35M	-$5.79	N/A
MacroGenics	$157.08M	1.55	-$74.62M	-$1.10	N/A

In the previous week, MacroGenics had 1 more articles in the media than ImageneBio. MarketBeat recorded 2 mentions for MacroGenics and 1 mentions for ImageneBio. MacroGenics' average media sentiment score of 1.00 beat ImageneBio's score of 0.00 indicating that MacroGenics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MacroGenics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImageneBio has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. ImageneBio's return on equity of -38.96% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
MacroGenics	-44.79%	-147.80%	-28.40%

ImageneBio has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

Summary

MacroGenics beats ImageneBio on 10 of the 17 factors compared between the two stocks.

How does ImageneBio compare to Sol-Gel Technologies?

ImageneBio (NASDAQ:IMA) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, ImageneBio had 1 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 1 mentions for ImageneBio and 0 mentions for Sol-Gel Technologies. ImageneBio's average media sentiment score of 0.00 equaled Sol-Gel Technologies'average media sentiment score.

Company	Overall Sentiment
ImageneBio	Neutral
Sol-Gel Technologies	Neutral

Sol-Gel Technologies has higher revenue and earnings than ImageneBio. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	75.08	-$45.35M	-$5.79	N/A
Sol-Gel Technologies	$19.39M	11.88	-$6.13M	-$0.34	N/A

ImageneBio has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

ImageneBio currently has a consensus target price of $30.00, indicating a potential upside of 431.91%. Sol-Gel Technologies has a consensus target price of $197.50, indicating a potential upside of 140.88%. Given ImageneBio's higher possible upside, research analysts clearly believe ImageneBio is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

ImageneBio has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Sol-Gel Technologies beats ImageneBio on 9 of the 15 factors compared between the two stocks.

How does ImageneBio compare to AC Immune?

AC Immune (NASDAQ:ACIU) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 2.2% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

AC Immune presently has a consensus price target of $7.50, indicating a potential upside of 237.84%. ImageneBio has a consensus price target of $30.00, indicating a potential upside of 431.91%. Given ImageneBio's higher probable upside, analysts plainly believe ImageneBio is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

ImageneBio has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. ImageneBio's return on equity of -38.96% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
ImageneBio	N/A	-38.96%	-34.60%

ImageneBio has lower revenue, but higher earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	52.42	-$85.03M	-$0.82	N/A
ImageneBio	$800K	75.08	-$45.35M	-$5.79	N/A

AC Immune has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

In the previous week, AC Immune had 1 more articles in the media than ImageneBio. MarketBeat recorded 2 mentions for AC Immune and 1 mentions for ImageneBio. AC Immune's average media sentiment score of 0.86 beat ImageneBio's score of 0.00 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ImageneBio beats AC Immune on 9 of the 17 factors compared between the two stocks.

How does ImageneBio compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Anavex Life Sciences' return on equity of -32.73% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-32.73%	-30.15%
ImageneBio	N/A	-38.96%	-34.60%

31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 75.0% of ImageneBio shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by insiders. Comparatively, 2.2% of ImageneBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Anavex Life Sciences has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

In the previous week, Anavex Life Sciences had 6 more articles in the media than ImageneBio. MarketBeat recorded 7 mentions for Anavex Life Sciences and 1 mentions for ImageneBio. Anavex Life Sciences' average media sentiment score of 0.62 beat ImageneBio's score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anavex Life Sciences currently has a consensus price target of $21.33, suggesting a potential upside of 623.16%. ImageneBio has a consensus price target of $30.00, suggesting a potential upside of 431.91%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Anavex Life Sciences is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

ImageneBio has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A
ImageneBio	$800K	75.08	-$45.35M	-$5.79	N/A

Summary

Anavex Life Sciences beats ImageneBio on 10 of the 15 factors compared between the two stocks.

How does ImageneBio compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 75.0% of ImageneBio shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by company insiders. Comparatively, 2.2% of ImageneBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Galectin Therapeutics' return on equity of 0.00% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
ImageneBio	N/A	-38.96%	-34.60%

Galectin Therapeutics has higher earnings, but lower revenue than ImageneBio. Galectin Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
ImageneBio	$800K	75.08	-$45.35M	-$5.79	N/A

Galectin Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

In the previous week, Galectin Therapeutics and Galectin Therapeutics both had 1 articles in the media. Galectin Therapeutics' average media sentiment score of 0.67 beat ImageneBio's score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Galectin Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 263.04%. ImageneBio has a consensus target price of $30.00, suggesting a potential upside of 431.91%. Given ImageneBio's stronger consensus rating and higher probable upside, analysts plainly believe ImageneBio is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Summary

ImageneBio beats Galectin Therapeutics on 8 of the 14 factors compared between the two stocks.

Get ImageneBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMA vs. The Competition

Export

Metric	ImageneBio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$59.03M	$3.55B	$6.86B	$12.44B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-0.97	7.29	280.74	24.99
Price / Sales	75.08	1,264.35	588.16	90.43
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	0.47	16.89	11.02	6.21
Net Income	-$45.35M	-$12.54M	$3.48B	$347.49M
7 Day Performance	-2.08%	0.31%	0.81%	1.29%
1 Month Performance	-3.26%	-7.40%	-4.15%	-3.59%
1 Year Performance	-66.02%	47.13%	61.47%	18.38%

ImageneBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMA ImageneBio	1.8605 of 5 stars	$5.64 +1.8%	$30.00 +431.9%	-67.4%	$59.03M	$800K	N/A	70
MGNX MacroGenics	2.8724 of 5 stars	$3.68 -4.5%	$5.50 +49.7%	+141.8%	$233.59M	$157.08M	N/A	430	News Coverage
SLGL Sol-Gel Technologies	4.3476 of 5 stars	$82.51 -0.7%	$197.50 +139.4%	+530.7%	$231.84M	$19.39M	N/A	50
ACIU AC Immune	2.4038 of 5 stars	$2.27 -2.0%	$7.50 +229.8%	+4.7%	$231.43M	$4.31M	N/A	140	Positive News
AVXL Anavex Life Sciences	1.703 of 5 stars	$2.50 -2.9%	$21.33 +755.0%	-73.7%	$231.21M	N/A	N/A	40	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMA) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImageneBio (IMA) Competitors

IMA vs. MGNX, SLGL, ACIU, AVXL, and GALT

How does ImageneBio compare to MacroGenics?

Summary

How does ImageneBio compare to Sol-Gel Technologies?

Summary

How does ImageneBio compare to AC Immune?

Summary

How does ImageneBio compare to Anavex Life Sciences?

Summary

How does ImageneBio compare to Galectin Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImageneBio (IMA) Competitors

IMA vs. MGNX, SLGL, ACIU, AVXL, and GALT

How does ImageneBio compare to MacroGenics?

Do insiders and institutionals have more ownership in IMA or MGNX?

Do analysts recommend IMA or MGNX?

Which has better earnings & valuation, IMA or MGNX?

Does the media favor IMA or MGNX?

Is IMA or MGNX more profitable?

Which has more volatility and risk, IMA or MGNX?

Summary

How does ImageneBio compare to Sol-Gel Technologies?

Does the media prefer IMA or SLGL?

Which has preferable earnings & valuation, IMA or SLGL?

Which has more risk & volatility, IMA or SLGL?

Do analysts rate IMA or SLGL?

Is IMA or SLGL more profitable?

Do insiders and institutionals believe in IMA or SLGL?

Summary

How does ImageneBio compare to AC Immune?

Do institutionals & insiders believe in ACIU or IMA?

Do analysts rate ACIU or IMA?

Is ACIU or IMA more profitable?

Which has stronger valuation & earnings, ACIU or IMA?

Which has more risk and volatility, ACIU or IMA?

Does the media favor ACIU or IMA?

Summary

How does ImageneBio compare to Anavex Life Sciences?

Is AVXL or IMA more profitable?

Do insiders and institutionals hold more shares of AVXL or IMA?

Which has more risk & volatility, AVXL or IMA?

Does the media favor AVXL or IMA?

Do analysts rate AVXL or IMA?

Which has higher valuation & earnings, AVXL or IMA?

Summary

How does ImageneBio compare to Galectin Therapeutics?

Do institutionals & insiders hold more shares of GALT or IMA?

Is GALT or IMA more profitable?

Which has higher earnings & valuation, GALT or IMA?

Which has more volatility and risk, GALT or IMA?

Does the media favor GALT or IMA?

Do analysts prefer GALT or IMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools